Growth and Pubertal Development Among HIV Infected and Uninfected Adolescent Girls in Lagos, Nigeria: A Comparative Cross-Sectional Study

David Agatha1, Gbaja-biamila Titilola1, Salako Abideen1, Odubela Oluwatosin1, Wapmuk Agatha1, Ekama Sabdat1, Musari-Martins Tomilola1, Ezemelue Priscilla1, Herbertson Ebiere1, and Ezechi Oliver1

Abstract
This study aimed to compare growth and pubertal developmental parameters among HIV-infected and uninfected adolescent girls (11-19 years) in Lagos using a cross-sectional approach. Height, weight, BMI Z-scores, sexual maturity rating by Tanner stages and age at menarche, were compared in the 2 groups. The mean age was similar in both groups (13.2 ± 2.3 years and 13.6 ± 1.6 years for HIV positive and negative respectively [P = .13]). Majority (66.2%) were in Junior Secondary classes and the mean socioeconomic class was 2.5 (± 0.9). HIV-infected girls had significantly lower height, weight, and BMI Z scores compared to their uninfected counterparts. The proportion that had attained Tanner stages 3 to 5 were significantly lower among the HIV-positive participants. The study identified lower growth parameters and pubertal delay among HIV-infected adolescent females compared to HIV uninfected girls. Growth and sexual maturation assessment should form part of routine care of adolescents living with HIV.

Keywords
HIV, adolescent, female, growth, puberty, delay, Nigeria

Received January 13, 2022. Accepted for publication February 3, 2022.

Introduction
HIV/AIDS remains a major global public health challenge almost 4 decades after its emergence in the early 1980s. However, improvements in diagnosis and treatment, especially access to highly active antiretroviral therapy, have turned a once lethal disease into a chronic manageable condition, with a reasonable prospect of long healthy lives for infected persons.1,2

This success has led to increased survival of children perinatally infected with HIV into adolescence and adulthood.3,4 Horizontal transmission of HIV to adolescents also contributes to the increasing numbers of adolescents living with HIV (ALHIV), raising the population by 30% from 2005 to 2016.5-7

However, the catabolic, chronic inflammatory, and immunosuppressive nature of HIV infection have raised concerns about its impact on the skeletal growth and pubertal maturation of infected adolescents. This concern is corroborated by observations of impaired growth and sexual maturation in adolescents with other chronic diseases such as sickle cell disease, severe asthma, cystic fibrosis, and chronic kidney disease.8-12 Onset at a younger age and greater severity of chronic illness have a greater negative effect on growth and sexual maturation.8

Several reasons are adduced for this growth and pubertal delay. The adverse effects of inflammatory markers and undernutrition on the growth hormone (GH)—insulin-like growth factor-1 (IGF-1) axis are thought to impact negatively on metabolic and
endocrine functions. Furthermore, low levels of the hormone leptin, resulting from poor nutrition and reduced energy reserves in chronic illness also have a negative effect on the hypothalamic-pituitary-gonadal axis, leading to reduced pulsatile release of gonadotrophin releasing hormone (GnRH) and disruptions in pubertal development.

In addition to the burden of chronic illness, growth, and pubertal delay in adolescents can also be associated with some long-term negative consequences, which include reduced adult height and bone mineral density, poor psychosocial functioning, and educational attainment, as well as increased susceptibility to metabolic and cardiovascular disorders. In view of this, early detection and efforts at mitigation of suboptimal growth and delayed sexual maturation should be part of the routine care of children with chronic illness.

While various studies have documented evidence of delayed growth and pubertal maturation among ALHIV, few of those studies have emanated from the West and Central Africa, which hosts the second-largest HIV epidemic, behind Southern and Eastern Africa. The region is also burdened with poverty and malnutrition, thus compounding the case for poor growth and pubertal delay among HIV-infected children and adolescents. Furthermore, HIV-positive adolescents (10-19-year-olds) make up 7.0% of the HIV-positive population in Nigeria. Thus, there is a significant population of HIV-infected adolescents in the country but limited reports on their growth and pubertal development.

There is evidence that prompt recognition and appropriate intervention can reverse growth delays in some adolescents with chronic illness so that they eventually attain expected adult height for their sex and racial groups. Several works have shown that combination antiretroviral therapy with improved nutrition among children with HIV infection is associated with positive trends with respect to growth. Assessment of growth and pubertal development in HIV-infected children and adolescents will help identify deficits if any, so that appropriate and timely interventions can be instituted. This study, therefore, aimed to compare growth and pubertal development among HIV infected and uninfected adolescent girls in Lagos State using anthropometric parameters and pubertal stages.

Methods

Study Design and Setting

This was a cross-sectional comparative study among female adolescents living with HIV [ALHIV] and accessing care at the HIV Care and Treatment Centre at the Nigerian Institute of Medical Research (NIMR), Yaba, and apparently healthy HIV uninfected adolescent girls at a girls’ only secondary school also at Yaba, in Lagos State, Nigeria. The NIMR HIV Centre, established in 2002, provides comprehensive HIV care and treatment services to adults, pregnant women, and children and had a cumulative enrollment of over 25 000 by the end of 2020. The Adolescent Clinic of the Centre, which commenced operations in 2014, attends to the clinical and psychosocial needs of male and female adolescents living with HIV.

Study Population

HIV-positive and negative female adolescents aged 10 to 19 years comprised the study population. Those who were acutely ill or who could not provide consent or assent were excluded from the study. The current onc-care patients attending the Adolescent HIV are 258, approximately 50.0% of whom are females. All eligible participants attending the clinic who provided consent/assent for the study were enrolled as participants. Using a 1:1 ratio of HIV positive and negative participants, the final study sample size was 115 female ALHIV and 118 apparently healthy HIV uninfected adolescents.

Study Procedure

After obtaining informed parental consent and assent from prospective participants aged <18 years and informed consent from those aged ≥18 years, sociodemographic characteristics including age, ethnicity, educational level, and parental education and occupation (used to calculate socioeconomic status according to the method by Oyedeji) was obtained with a questionnaire. Menstruation status and age at menarche, if already attained, were recorded in the questionnaire. Thereafter the height (to the nearest 0.5 cm) and weight (to the nearest 0.1 kg) were measured with the participant lightly clothed and on bare feet with the Seca weight and height meter combination (Seca GMBH & co. kg. 22089 Hamburg, Germany). The body mass index (BMI) was calculated from the weight and height values. The Z scores for age for height, weight, and BMI were obtained using the WHO growth charts and the Pedz Pediatric Body Percentile Calculator.

Pubertal maturation was assessed by visual inspection using the 5 stages of breast and pubic hair development described by Marshal and Tanner (Tanner Stages). Images of the different Tanner stages for breast development and pubic hair development were compared with each participant’s breast and pubic hair and used to assign the breast and pubic hair stage for that participant. Only 1 member of the study team performed the
visual examination for breast and pubic hair stage to avoid inter-observer error. The observed stages were recorded in the participants’ case report form.

**Data Management**

Study data were entered into a Microsoft Excel spreadsheet, cleaned, and transferred to SPSS for windows (version 23) software for analysis. Student’s t-test and Chi-square test were used to compare population means and population proportions between the 2 groups respectively. The level of significance (α) was set at 0.05.

The proportion of participants that had attained menarche and the mean age at menarche was compared between the 2 groups. The effect of growth parameters on menarche status was also compared between the 2 groups.

**Ethical Consideration**

Ethical approval for the study was obtained from the NIMR Institutional Review Board and permission obtained from the management of the mission school.

Parents were informed about the study at a Parents/Teachers Association (PTA) meeting and students were given the parental informed consent form to take home for parental consent. Participants below 18 years of age signed an assent form in addition to parental consent.

Inability to provide parental consent/assent made the student ineligible to participate in the study. The consenting process took place at the HIV clinic for the participants living with HIV.

Privacy and confidentiality were maintained; the visual observation for the Tanner staging was conducted in the consulting room of either the mission school clinic or the HIV clinic as appropriate. Study data were de-identified as only study numbers were used to identify participants.

**Results**

**Socio-Demographic Characteristics of Study Participants**

Table 1 gives the details of the sociodemographic characteristics of the 233 study participants. The mean age of all participants was 13.4 (±2.0) years, and this was similar across the 2 groups of participants (13.2 [±2.3] years vs 13.6 [±1.6] years in the HIV infected and uninfected respectively).

The proportion of participants that had attained menarche and the mean age at menarche was compared between the 2 groups. The effect of growth parameters on menarche status was also compared between the 2 groups.

| Characteristic       | All frequency (%)/Mean (±SD) | HIV positive frequency (%)/Mean (±SD) | HIV negative frequency (%)/Mean (±SD) | OR [95% CI] | P value |
|----------------------|-------------------------------|-------------------------------------|--------------------------------------|-------------|---------|
| Age (years)          |                               |                                     |                                      |             |         |
| Mean                 | 13.4 (±2.0)                   | 13.2 (±2.3)                         | 13.6 (±1.6)                          |             | .13     |
| Education            |                               |                                     |                                      |             |         |
| ≤Basic 9             | 151 (66.2)                    | 83 (76.1%)                          | 67 (56.8%)                           | 2.43 [1.37-4.30] | .002    |
| >Basic 9             | 77 (33.8)                     | 26 (23.9%)                          | 51 (43.2%)                           |             |         |
| Orphan status        |                               |                                     |                                      |             | <.001   |
| S/D Orphan#          | 41 (17.6)                     | 38 (33.0)                           | 3 (2.5)                              | 18.91 [5.64-63.45] | <.001   |
| Parents Alive        | 192 (82.4)                    | 77 (67.0)                           | 115 (97.5)                           |             |         |

*Mean (±SD): Mean (±standard deviation).

!OR [95% CI]: Odds Ratio [95% Confidence Interval].

*S/D Orphan: Single/Double Orphan.

The anthropometric parameters of height, weight, and body mass index (BMI) were used to assess growth among the participants. The mean Z scores for all the participants were −0.69 (±1.5), −0.59 (±1.69), and −0.25 (±1.4) for height, weight, and BMI respectively. The mean Z scores for height, weight, and BMI were all significantly lower among the HIV-positive participants.
Significantly higher proportions of HIV positive participants had Z scores \( \leq -1.0 \) (67.2% vs 14.4%), (59.1% vs 12.7%), (37.4% vs 5.1%) for height, weight, and BMI respectively, than their HIV negative counterparts \((P < .001)\) as depicted in Table 2.

### Pattern of Pubertal Development Among Study Participants

Pubertal development was assessed by breast and pubic hair development using the Tanner Staging for pubertal development. For breast development, the majority of participants were in Stage 3 (29.5% and 50.0% for the HIV positive and negative respectively) while for pubic hair development majority of HIV positive adolescents (26.1%) were in stage 2 and a majority of HIV negative adolescents (60.9%) were in stage 4. HIV-positive participants were significantly less likely to be in Tanner stages 3 to 5 for both breast and pubic hair development than HIV negative participants (50.4% vs 94.1% and 21.7% vs 93.2% respectively; \(P < .001\)).

The mean age at menarche was also significantly higher among the HIV-positive participants \( (13.2 \pm 1.7) \) years vs \( 11.8 \pm 1.1 \) years; \(P = .002\)). The proportion of participants that had attained menarche was significantly lower in the HIV-positive participants \( (41.7\% \text{ vs } 83.1\%); \(P < .001\)\).

The proportion that had attained menarche increased with increasing age in the 2 groups. However, the proportion that had attained menarche was significantly lower in the HIV-positive participants in the 10 to 12-year and 13 to 15-year age groups \((P < .001)\). All HIV-negative participants in the 16 to 19-year age group had attained menarche, compared to 77.8% in the HIV-positive participants.

The pattern of pubertal development among the study participants is shown in Table 3.

### Menarche Status and Anthropometric Parameters in ALHIV

We compared the proportion of adolescent participants living with HIV who had attained menarche and the mean age at menarche at Z scores \( \leq -1 \) and \( > -1 \) for height, weight, and body mass index parameters.

Participants with BMI Z scores \( \leq -1 \) had significantly lower proportion who had attained menarche \((23.8\% \text{ vs } 52.1\%); \text{ OR } [95\% \text{ CI}]: 0.29 \pm 0.67, \text{ and } P = .009\) and a higher mean age at menarche compared to those with Z scores \( > -1 \) \((14.3 \pm 1.8) \text{ years vs } 13.0 \pm 1.5 \text{ years}; P = .021\).

For height and weight Z scores, while the proportion with menarche was significantly lower in those with weight Z scores \( \leq -1 \) \((P = .001)\), there was no significant difference for those with height Z scores \( \leq -1 \text{ or } > -1 \) \((P = .491)\).

Similarly, while the mean age at menarche was significantly higher in those with weight Z scores \( \leq -1 \) \((P = .001)\), there was no significant difference in those with height Z scores \( \leq -1 \) \text{ or } > -1 \) \((P = .151)\). This is described in Table 4.

### Discussion

Growth and pubertal development are an important index of health among the adolescents that requires close attention especially among individuals with chronic illnesses such as HIV infection. The study compared the growth and pubertal development of adolescent girls living with HIV and age-matched HIV uninfected girls in Lagos,
### Table 3. Pattern of Pubertal Development Among Study Participants.

| Variables                  | HIV positive frequency (%) | HIV negative frequency (%) | OR [95% CI] | P value |
|----------------------------|-----------------------------|----------------------------|-------------|---------|
| Breast stage               |                             |                            |             |         |
| 1-2                        | 54 (49.6)                   | 7 (5.9)                    | 14.04       | <.001   |
| 3-5                        | 61 (50.4)                   | 111 (94.1)                 | [6.02-32.75] |         |
| Pubic hair stage           |                             |                            |             |         |
| 1-2                        | 52 (78.3)                   | 8 (6.8)                    | 11.35       | <.001   |
| 3-5                        | 63 (21.7)                   | 110 (93.2)                 | [5.07-25.42] |         |
| Menarche status            |                             |                            |             |         |
| Yes                        | 48 (41.7)                   | 98 (83.1)                  | 0.15        |         |
| No                         | 67 (58.3)                   | 20 (16.9)                  | [0.08-0.27] |         |
| Age at menarche (years)    |                             |                            |             | .002    |
| Mean                       | 13.2 (1.7)                  | 11.8 (1.1)                 |             |         |
| Menarche status in age groups |                         |                            |             |         |
| 10-12 years                |                             |                            |             | .002    |
| Pre-menarche               | 44 (86.3)                   | 18 (56.3)                  | 4.89        |         |
| Menarche                   | 7 (13.7)                    | 14 (43.7)                  | [1.69-11.1] |         |
| 13-15 years                |                             |                            |             | <.001*  |
| Pre-menarche               | 20 (43.5)                   | 2 (2.7)                    | 27.69       |         |
| Menarche                   | 26 (56.5)                   | 72 (97.3)                  | [6.05-126.76]|         |
| 16-19 years                |                             |                            |             |         |
| Pre-menarche               | 4 (22.2)                    | 0 (0.0)                    |             |         |
| Menarche                   | 14 (77.8)                   | 12 (100.0)                 |             |         |

| Characteristics            | Z score ≤ −1 | Z score > −1 | OR [95% CI] | P value |
|----------------------------|--------------|--------------|-------------|---------|
| **BMI**                    |              |              |             |         |
| Age (years)                |              |              |             | .203    |
| Mean (±SD)                 | 13.5 (±2.3)  | 13.0 (±2.4)  |             |         |
| Menarche status            |              |              |             |         |
| Menarche                   | 10 (23.8)    | 38 (52.1)    |             | .021    |
| Pre-menarche               | 32 (76.2)    | 35 (47.9)    |             |         |
| Age at menarche            |              |              |             | .003    |
| Mean (±SD)                 | 14.3 (±1.8)  | 13.0 (±1.5)  |             |         |
| **Height**                 |              |              |             |         |
| Age (years)                |              |              |             | .021    |
| Mean (±SD*)                | 13.5 (±2.2)  | 12.5 (±2.4)  |             |         |
| Menarche status            |              |              |             | .491    |
| Menarche                   | 30 (39.5)    | 18 (46.2)    |             |         |
| Pre-menarche               | 46 (60.5)    | 21 (53.8)    |             |         |
| Age at menarche            |              |              |             | .026    |
| Mean (±SD)                 | 13.7 (±1.5)  | 12.6 (±1.6)  |             |         |
| **Weight**                 |              |              |             |         |
| Age (years)                |              |              |             | .916    |
| Mean (±SD)                 | 13.2 (±1.7)  | 13.2 (±2.9)  |             |         |
| Menarche status            |              |              |             | .009    |
| Menarche                   | 19 (30.6)    | 29 (54.7)    |             |         |
| Pre-menarche               | 43 (69.4)    | 24 (45.3)    |             |         |
| Age at menarche            |              |              |             | .151    |
| Mean (±SD)                 | 13.7 (±1.1)  | 13.0 (±1.9)  |             |         |

1 OR [95% CI]: Odds Ratio [95% Confidence Interval].
2 Fishers Exact.

### Table 4. Menarche Status and Anthropometric Parameters in ALHIV.

| Characteristic                | Z score ≤ −1 | Z score > −1 | OR [95% CI] | P value |
|------------------------------|--------------|--------------|-------------|---------|
| **BMI**                      |              |              |             |         |
| Age (years)                  |              |              |             | .203    |
| Mean (±SD)                   | 13.5 (±2.3)  | 13.0 (±2.4)  |             |         |
| Menarche status              |              |              |             | .003    |
| Menarche                     | 10 (23.8)    | 38 (52.1)    |             |         |
| Pre-menarche                 | 32 (76.2)    | 35 (47.9)    |             |         |
| Age at menarche              |              |              |             | .021    |
| Mean (±SD)                   | 14.3 (±1.8)  | 13.0 (±1.5)  |             |         |
| **Height**                   |              |              |             |         |
| Age (years)                  |              |              |             | .021    |
| Mean (±SD*)                  | 13.5 (±2.2)  | 12.5 (±2.4)  |             |         |
| Menarche status              |              |              |             | .491    |
| Menarche                     | 30 (39.5)    | 18 (46.2)    |             |         |
| Pre-menarche                 | 46 (60.5)    | 21 (53.8)    |             |         |
| Age at menarche              |              |              |             | .026    |
| Mean (±SD)                   | 13.7 (±1.5)  | 12.6 (±1.6)  |             |         |
| **Weight**                   |              |              |             |         |
| Age (years)                  |              |              |             | .916    |
| Mean (±SD)                   | 13.2 (±1.7)  | 13.2 (±2.9)  |             |         |
| Menarche status              |              |              |             | .009    |
| Menarche                     | 19 (30.6)    | 29 (54.7)    |             |         |
| Pre-menarche                 | 43 (69.4)    | 24 (45.3)    |             |         |
| Age at menarche              |              |              |             | .151    |
| Mean (±SD)                   | 13.7 (±1.1)  | 13.0 (±1.9)  |             |         |

1 OR [95% CI]: Odds Ratio [95% Confidence Interval].
2 SD: standard deviation.
Nigeria. Findings showed significantly lower growth parameters (height, weight, and BMI Z scores) among the HIV-infected participants. HIV-positive participants were also significantly more likely to be in lower Tanner stages (1 and 2) for both breast and pubic hair development than HIV-negative participants (49.6% and 48.7% compared to 5.9% and 7.3% respectively; \( P < .001 \)). Furthermore, HIV-infected participants attained menarche significantly later than their HIV-negative counterparts (13.2 [±1.7] years vs 11.8 [±1.1] years; \( P = .002 \)). The proportion of HIV-positive participants that had attained menarche was also significantly lower. For HIV-infected participants, height, weight, and BMI Z score \( \leq -1 \) scores were all associated with higher age at menarche.

The poor growth pattern among adolescents living with HIV in our study is similar to findings from sub-Saharan Africa, Europe, and the USA.\(^{31-33} \) However, the marked difference between our 2 cohorts could be attributed to the poorer socioeconomic status and higher orphan status of the HIV-positive cohort, with consequent poorer nutritional intake, as well as the malabsorption, and recurrent infections associated with HIV infection.

While the early institution of antiretroviral therapy is one of the strategies to prevent or mitigate growth impairment in HIV-positive children and adolescents, studies have shown that already established growth impairment can persist despite the commencement of antiretroviral drugs.\(^{31} \) Our findings buttress this observation, as all our HIV participants were on antiretroviral drugs and still showed significantly reduced growth parameters compared with their HIV-negative counterparts.

The delayed pubertal development (as demonstrated by breast and pubic hair stages of sexual maturation) and increase in mean age at menarche of 1.4 years (from 11.8 years in the HIV uninfected to 13.2 years) among the HIV-infected participants in our study is per findings from similar studies from within and outside the African continent.\(^{16-21,31-33} \) Reasons for this delay could be the lowering effect of poor nutrition and proinflammatory cytokines on leptin hormone levels and pulsatile release of gonadotrophin releasing hormone (GnRH) leading to disruptions in pubertal development as described by other workers.\(^{12-14} \)

In conclusion, the findings buttress the need for continued close monitoring, evaluation, and prompt management of the adolescent living HIV by the primary caregiver and healthcare providers to enable early detection of poor growth and delayed sexual maturation and institution of appropriate management strategies to optimize survival and quality of life.

**Limitation**

The study did not include male HIV positive and HIV negative adolescents so the effect of HIV on growth and pubertal development among male adolescents could not be assessed. This will be addressed in future studies.

**Acknowledgments**

The authors acknowledge the help of Oba Abdulrasheed with the statistical analysis.

**Author Contributions**

David Nkiru: Conception of study, developed and supervised data extraction and findings, and wrote the manuscript.

Gbaja-biamila Titilola: Conception of study, developed and supervised data extraction and findings, and wrote the manuscript.

Salako Abideen: Conception of study, developed and supervised data extraction and findings, and wrote the manuscript.

Odubela Oluwatosin: Conception of study, developed and supervised data extraction and findings, and wrote the manuscript.

Wapmuk Agatha: Carried out the study, analysis of work, helped shape the research findings, provided critical feedback and wrote the manuscript.

Ekama Sabdat: Carried out the study, analysis of work, helped shape the research findings, provided critical feedback and wrote the manuscript.

Musari-Martins Tomilola: Carried out the study, analysis of work, helped shape the research findings, provided feedback and wrote the manuscript.

Ezemelue Priscilla: Carried out the study, analysis of work, helped shape the research findings, provided critical feedback and wrote the manuscript.

Hebertson Ebiere: Supervised and reviewed the findings of the study, provided critical feedback and helped shape the research, analysis, and manuscript.

Ezechii Oliver: Supervised and reviewed the findings of the study, provided critical feedback and helped shape the research, analysis, and manuscript.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical Approval
Ethical approval for the study was obtained from the NIMR Institutional Review Board and permission obtained from the management of the mission school.

ORCID iD
Odubela Oluwatosin https://orcid.org/0000-0002-4432-9137

References
1. UNAIDS. Global HIV & AIDS Statistics – Fact sheet. Accessed March 5, 2021. www.unaids.org/en/resources/fact-sheet
2. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012;2:a007161. doi:10.1101/cshperspect.a007161
3. Lowenthal ED, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand RA. Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. Lancet Infect Dis. 2014;14(7):627-639.
4. The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration, Slogrove AL, Sehomaker M, Davies MA, et al. The epidemiology of adolescents living with perinatally acquired HIV: a cross-region global cohort analysis. PLoS Med. 2018;15(3):e1002514.
5. Rohkmahn D. The role of sexual behavior in the transmission of HIV and AIDS in adolescent in coastal area. Procedia Environ Sci. 2015;23:99-104. doi:10.1016/j.proenv.2015.01.015
6. Belle JA, Gamedze NN. Behavioral factors contributing to the transmission of HIV and AIDS amongst young women of Mbahane in Swaziland. Afr Health Sci. 2019;19(3):2302-2311. doi:10.4314/ahs.v19i3.2
7. Avert. Young people, HIV and AIDS. Accessed April 3, 2021. https://www.avert.org/professionals/hiv-social-issues/key-affected-populations/young-people
8. Pozo J, Argente J. Delayed puberty in chronic illness. Best Pract Res Clin Endocrinol Metab. 2002;16:73-90. doi:10.1053/beem.2002.0182
9. Tang C, Damian M. Delayed Puberty. In StatPearls [Internet]. StatPearls Publishing; 2019.
10. Kim HS, Ng DK, Matheson MB, et al. Delayed menarche in girls with chronic kidney disease and the association with short stature. Pediatr Nephrol. 2020;35:1471-1475.
11. Suris JC, Michaud PA, Viner R. The adolescent with a chronic condition. Part I: developmental issues. Arch Dis Child. 2004;89(10):938-942.
12. Patel L. Growth and chronic disease. An Nestle. 2007;65:129-136. doi:10.1159/000112235
13. Parent AS, Lefebrethon MC, Gérard A, Vandersmissen E, Bourguignon JP. Leptin effects on pulsatile gonadotropin releasing hormone secretion from the adult rat hypothalamus and interaction with cocaine and amphetamine regulated transcript peptide and neuropeptide Y. Regul Pept. 2000;92(1-3):17-24. doi:10.1016/s0167-0115(00)00144-0
14. Soliman A, De Sanctis V, Elalati R, Bedair S. Advances in pubertal growth and factors influencing it: can we increase pubertal growth? Indian J Endocrinol Metab. 2014;18(Suppl 1):SS3-S62. doi:10.4103/2230-8210.145075
15. Zhu J, Chan YM. Adult consequences of self-limited delayed puberty. Pediatrics. 2017;139(6):e20163177.
16. de Martino M, Tovo P-A, Galli L, et al. Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS. 2001;15:1527-1534.
17. Buchacz K, Rogol AD, Lindsey JC, et al. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. J Acquir Immune Defic Syndr. 2003;33:56-65.
18. Williams PL, Abzug MJ, Jacobson DL, et al. Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment. AIDS. 2013;27:1959-1970.
19. Bakeera-Kitaka S, McKellarb M, Sniderb C, et al. Antiretroviral therapy for HIV-1 infected adolescents in Uganda: assessing the impact on growth and sexual maturation. J Pediatric Infect Dis. 2008;3:99-104.
20. Chantry CJ, Frederick MM, Meyer WA 3rd, et al. Endocrine abnormalities and impaired growth in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2007;26:53-60.
21. Khalifa A, Stover J, Mahy M, Idele P, Porth T, Lwamba C. Demographic change and HIV epidemic projections to 2050 for adolescents and young people aged 15-24. Glob Health Action. 2019;12(1):1662685. doi:10.1080/16549716.2019.1662685
22. UNICEF. West and Central Africa. Malnutrition. www.unicef.org/wca/malnutrition
23. Avert - Avert.org. HIV and AIDS in Nigeria. Accessed April 11, 2021. https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/nigeria
24. WHO. Guideline for an Integrated Approach to the Nutritional Care of HIV-Infected Children (6months-14 years): Handbook, Chart Booklet and Guideline for Country. World Health Organization; 2009. http://wwwapps.who.int/iris/bitstream/handle/1065/44043/9789241597524_eng_Handbook.pdf?sequence=1&isAllowed=y
25. de Martino M, Tovo P-A, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register of HIV Infection in Children and the Italian National AIDS Registry. JAMA. 2000;284:190-197.
26. Oyedeji GA. Socioeconomic and cultural background of hospitalized children in Ilesa. Niger J Paediatr. 1985;12(4):111-117.
27. WHO. The WHO child growth standards. www.who.int/tools/child-growth-standards/standards
28. Pediatric calculator - Ped(z) www.pedz.de/en/welcome.html
29. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in girls. *Arch Dis Child*. 1969;44:291-303.

30. Williams PL, Jesson J. Growth and pubertal development in HIV-infected adolescents. *Curr Opin HIV AIDS*. 2018;13(3):179-186.

31. Jacobson DL, Patel K, Siberry GK, et al. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the pediatric HIV/AIDS Cohort Study. *Am J Clin Nutr*. 2011;94(6):1485-1495.

32. Bellavia A, Williams PL, DiMeglio LA, et al. Delay in sexual maturation in perinatally HIV-infected youths is mediated by poor growth. *AIDS*. 2017;31(9):1333-1341.

33. Mbwile GR. *Growth and Pubertal Development Among HIV Infected Children Aged 8-18 Years in Dar es salaam*. Doctoral dissertation, Muhimbili University of Health and Allied Sciences; 2012.